Green Cross to build cell therapy manufacturing facility in China

South Korean biopharma company Green Cross (006280: Korea SE) says it plans to build a new cell therapy manufacturing facility at the Guian New Area in the Guizhou province of China. The new manufacturing site sets to address the cellular therapeutic industry's demand for clinical studies and commercial supply.

Green Cross says it has a robust and growing portfolio of approved and clinical stage cell therapy projects including T cell, NK cell, dendritic cell and stem cells. Cell therapy products are an increasingly significant tool in the treatment of serious diseases.

"Our investment reflects the strength of our business and the increasingly important role that cell therapy will play in Green Cross' future," said BG Rhee, president of Green Cross Holdings, adding: "Over the last 20 years, Green Cross has maintained a significant manufacturing facility and sales forces for plasma fractionation business in China, and we look forward to building on that legacy through this business expansion."